Call us now:
Establishing Biotech Company in Thailand
Thailand is rapidly cultivating a strategic position for biotechnology across Southeast Asia, powered by robust governmental encouragement, beneficial investment motives, and a maturing regulatory landscape. Venturers aiming to initiate a biotech company in Thailand will discover a legal framework that inspires progress while sustaining regulatory adherence and international investment oversight.
Central to the lawful arrangement is the Foreign Business Act B.E. 2542 (1999), which usually restricts foreigners from participating in specified sectors unless they obtain a Foreign Business License (FBL) or benefit from promotional privileges granted by the Thailand Board of Investment. Thankfully, biotech-related activities are among those that qualify for BOI sponsorship under certain classifications, allowing foreign investors to operate with up to 100% ownership and receive a suite of incentives such as corporate earnings tax exemptions, import tariff waivers, and facilitated visa and work permit procedures.
The Investment Promotion Act B.E. 2520 (1977), administered by the BOI, plays a pivotal role in encouraging the advancement of advanced technologies, including bioplastics, biochemicals, and biotechnology R&D. Biotech companies that fall under BOI categories 1.5.1, 1.5.2, or 1.6 can benefit from strong fiscal advantages, provided they meet criteria related to funding, local employment, and technological innovation.
Thailand’s legal environment is reinforced by strategic policies such as the Thailand 4.0 vision and the National Biotechnology Policy Framework, both of which prioritize biotech as a driver of sustainable and high-value economic growth. The presence of leading research institutions like TCELS and NSTDA further enhances the country’s ecosystem for R&D partnerships and innovation.
In summary, the Thai legal and institutional framework offers an attractive foundation for launching and scaling biotech operations, provided businesses navigate the legal requirements with precision and secure the appropriate licenses or BOI incentives.
Table of Contents
Why establish a biotech company in Thailand?
Beyond its legal framework, the country has become a strategic destination for establishing a biotech company due to strong government support, a skilled workforce integrated into global supply chains. Under the Thailand 4.0 economic model, biotech sits at the core of becoming an innovation-driven economy. Coupled with BOI incentives, the National Biotechnology Policy Framework actively promotes foreign projects, especially those involving agricultural, pharmaceutical, and green technologies.
Moreover, Thailand benefits from a growing network of research organizations offering public-private partnerships and grants, including the Thailand Center of Excellence for Life Sciences and the National Science and Technology Development Agency. Access to raw materials, low-cost yet highly educated talent, and regional trade agreements make Thailand compelling for establishing and expanding biotech operations across Southeast Asia.
Legal Structure suitable for a Biotech Company in Thailand
When incorporating a biotech company in Thailand, carefully selecting the proper legal structure is key to ensure regulatory adherence and BOI incentive eligibility. Foreign investors commonly opt for a Thai limited company thanks to its flexibility and compatibility with BOI schemes. A limited company demands at least three shareholders and can be wholly foreign-owned or mostly Thai depending on industry and the Foreign Business Act’s foreign ownership rules. If the company plans activities on List 2 or 3, a Foreign Business License may be needed unless qualifying for BOI promotion.
For biotech company in Thailand, pursuing BOI promotion typically means benefits like exemptions on foreign ownership limits, import tariffs, and corporate tax. The company must submit a detailed proposal to the BOI outlining biotech activities, investment amount, technology usage, and economic impact forecast.
Once established, the legal entity must follow Thai labor, tax, and accounting regulations. Additionally, companies conducting biotech research or production require licenses from authorities such as the Food and Drug Administration, Ministry of Public Health, and National Science and Technology Development Agency depending on activities.
Get expert legal guidance.
Overview of BOI-promoted Categories for Biotech Company in Thailand
The BOI provides categories uniquely supporting biotech company in Thailand growth and maturation. These activity list categories link to fiscal and non-fiscal incentives relative to a project’s scale and national development contributions. The following sections examine key relevant BOI categories, presenting specific conditions and benefits for qualifying ventures.
Manufacture of Bioplastic or Products from Bioplastic (1.5.1)
This BOI category supports the establishment of a biotech company in Thailand involved in the production of bioplastic materials or products manufactured from bioplastics. Projects under this category benefit from strong tax incentives and demonstrate the Thai government’s commitment to promoting sustainable and circular bioeconomy industries.
The advantages of this category include eligibility for the A2 or A3 incentive group, depending on the project’s nature and meeting certain international standards. For example, companies that manufacture bioplastics through a continual and certified process within the same project may be entitled to an 8-year corporate income tax exemption under category A2. Import duty exemptions on machinery and raw materials used in the production process are also granted. Projects that manufacture products from bioplastics involving plastic forming and ensuring certified bio-based content standards are eligible under category A3, offering 5 years of corporate income tax exemption. In both cases, certification must be obtained before full operation to qualify.
The biotech company in Thailand must demonstrate environmentally sustainable methods ensuring production aligns with international bioplastic standards. This includes obtaining certifications confirming bio-based content and degradable properties. The focus on innovation, sustainability, and circular raw materials use aligns these projects with the government’s vision for a Bio-Circular-Green model.
Manufacture of Biochemicals (1.5.2)
This category supports the establishment of a biotech company in Thailand manufacturing biochemicals using raw materials derived from biomass, agricultural waste, or byproducts from agricultural processing industries. The BOI recognizes the strategic importance of this sector in reducing dependency on petrochemical inputs and cultivating green industry development.
Companies employing this category must be certain that no less than 51% of the complete weight of enter materials are agricultural in beginning. This might include biomass, unintended products of agricultural processes, or handled agricultural materials. Significantly, initiatives involving only blending or dilution processes are left out from admissibility.
To meet the mandatory expectations, the biotech company in Thailand must too obtain global certification of biodegradability, such as those furnished under the OECD Guidelines for the Testing of Chemicals (e.g., OECD Test No. 301 for Ready Biodegradability). Certification must be in place prior to the functional get started date.
Projects assembly these circumstances are apt for BOI promotion under class A2. This presents a corporate cash flow tax exemption for 8 years, in improvement to import duty exemptions on machinery. These fiscal positive aspects are essential for biotech companies running in the preliminary phases of scale-up and commercialization.
Thailand’s emphasis on biochemical expansion stems from its all-natural resource abundance and the government’s aim to cultivate industries with decreased environmental footprints. Biotech companies in this field add significantly to the bioeconomy through creativity in green chemicals, biofuels, and specialty biomaterials.
Biotechnology Development (1.6)
This BOI class is specifically targeted at research-intensive biotech companies developing new technologies for application in key sectors such as healthcare, agriculture, or environmental science. Initiatives under this classification are able for the highest tier of BOI incentives, namely the A1+ category.
The main benefit of the A1+ category is a 10-year corporate income tax exemption with no cap on the exempted amount. This is especially appealing to startups and R&D centers focusing on long-term innovation. Additional incentives include non-tax benefits such as visa and work permit facilitation for foreign experts, and import duty exemptions on R&D equipment.
To qualify for this category, the biotech company in Thailand must be engaged in technology development procedures that directly support the production or services in BOI-targeted industries. The BOI mandates formal collaboration with Thai academic institutions through technology transfer. Acceptable partnerships include joint research initiatives, educational alliances, or structured training programs.
A successful application will detail research protocols, objectives and measurable outputs in extensive detail. The proposal must demonstrate how discoveries will bolster Thailand’s biomanufacturing infrastructure and industrial skills. The BOI closely examines whether the proposed initiative can aid the nation’s self-sufficiency and global competitiveness through science.
Conclusion
In summary, starting a biotech company in Thailand presents many advantages, from favorable investment policies and strategic geographical placement to access to trained labor and state-supported innovation resources. The organizational structure commonly chosen is a Thai limited company, allowing BOI incentives and regulatory alignment.
The BOI promotes biotech investment through three categories: biochemical manufacture, bioplastic production, and biotechnology development. Every category delivers particular fiscal and non-fiscal incentives dependent on technical specifications and adherence to global standards.
Foreign investors wanting to pioneer or enlarge a biotech enterprise in Thailand should seek qualified counsel to navigate the application process, meet eligibility needs, and ensure compliance with all licensing and regulatory conditions. With proper strategic planning and comprehension of the BOI framework, Thailand is fertile ground for biotechnology innovation.